Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Next Previous
Trial Profile

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Clofarabine; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Hydrocortisone sodium succinate; Mercaptopurine; Methotrexate; Methotrexate; Pegaspargase; Prednisone; Prednisone; Tioguanine; Vincristine
  • Indications CNS cancer; Leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Testicular cancer
  • Focus Therapeutic Use

Most Recent Events

  • 13 Nov 2024 Planned End Date changed from 22 Sep 2024 to 3 Oct 2025.
  • 12 Dec 2023 Results assessing response of Dasatinib following induction of patients with ABL-class fusion B-ALL, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 26 Sep 2023 Planned End Date changed from 27 Jan 2024 to 22 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top